Graham tells FDA to pull 'toxic' Ketek from market

Share this article:
FDA drug safety expert, whistleblower Dr. David Graham, has called on FDA officials to pull from the market Sanofi-Aventis' controversial antibiotic Ketek, saying it is as toxic, "if not more so," as three other drugs [Rezulin, Trovan and Duract] pulled from the market for liver problems. The FDA has already revised Ketek's labeling.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.